Alzheimer's Disease Dementia
Conditions
Interventions
Memantine a NMDA recptor antagonst and Lorazepam, a GABA agonsist and a placebo
will be adminsitered to the participants on tree seperape occasions.
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Is aged >= 21 to
Exclusion criteria
Exclusion criteria: • Known, or pre-existing, seizure disorder; • Previously confirmed EEG abnormality; • Space-occupying lesion, on history or confirmed by imaging modalities; • Substance abuse or substance dependence. • Pregnancy • Use of medication/s known to cause EEG alterations. • Systolic blood pressure >165 mmHg or diastolic blood pressure >95 mmHg whilst receiving optimal antihypertensive therapy according to local practice. • Any clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study. • Use of any investigational agent within 30 days or 5 half-lives (whichever is longer) prior to the screening visit. • History of alcohol abuse or of drug abuse within the past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EEG paradigms - 40 Hz steady state response - music listening - movie watching - story listening - resting state - P300 paradigm - CNV Cognitive testing - Verbal learning task Immediate recall Delayed recall after 45 minutes - Simple Reaction time task - Choice reaction time task For more detailed information see chapter 4 of the study protocol. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mood Rating - Subjective attention scale - Profile of Mood Scale Blood sampling A blood sample of 5 ml is taken via vena puncture. This sample will be centrifuged at 4°C 4000 rpm for 10 minutes. The blood plasma will used to examine the pharmacodynamic properties of the medications used. The blood samples will be stored at freezing temperature at -80 °C until analysis. | — |
Countries
Netherlands
Outcome results
None listed